Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum.

Abstract

Information on the effect of a third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in advanced CKD is incomplete (1). We assessed the humoral response up to 6 months after receipt of two or three doses of the SARS-CoV-2 vaccine across the CKD spectrum. SENOVAC is a prospective, multicentric study of cohorts of patients with CKD: kidney transplant, hemodialysis (HD), peritoneal dialysis (PD), and nondialysis CKD (eGFR <30 ml/min per 1.73 m2) (2,3). Patients were vaccinated against SARS-CoV-2 during routine clinical care. Some patients received a third dose of an mRNA vaccine. This depended on the timing of vaccination drives by local health authorities. We assessed anti-Spike antibodies (CLIA, Covid-19 Spike Quantitative Virla IgG Monotest; Vircell SL, Spain) kinetics at a prespecified 6-month time point after completing the original vaccination schedule (2,3). The study was approved by the ethics committee of Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (ISFJD) (February 2021).